Leading medical groups sue RFK Jr and HHS over ‘hostile’ vaccine policies
Several leading medical organisations have filed a lawsuit against US health Secretary Robert F Kennedy (RFK) Jr and the US…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a news and features reporter for Pharmaceutical Technology and Medical Device Network. Robert holds a BSc in Neuroscience and holds interests in neurological devices, infectious diseases, and company investment such as initial public offerings (IPOs). Contact Rob
-
-
J&J eyes prostate cancer label expansion for Akeega
Johnson & Johnson (J&J) has applied to the European Medicines Agency (EMA) to extend the indication of Akeega (niraparib and…
-
AstraZeneca’s Imfinzi approved in Europe for muscle-invasive bladder cancer
AstraZeneca has added another indication to its blockbuster immunotherapy Imfinzi (durvalumab), gaining European approval to treat a type of bladder…
-
Big pharma braces for revenue headwinds as patent expiries loom
One of the biggest patent cliffs is set to hit the pharmaceutical industry this decade, with major players bracing for…
-
Theratechnologies shares surge 25% amid $254m Future Pak takeover
Contract manufacturer Future Pak will acquire Theratechnologies in a $254m deal, bringing an end to a drawn-out sale process of…
-
Regeneron nabs dosing edge with Lynozyfic’s FDA approval in multiple myeloma
Regeneron has won US Food and Drug Administration (FDA) approval for Lynozyfic (linvoseltamab-gcpt), marking the entry of another BCMAxCD3 bispecific…
-
Analysis shows Yeztugo approval a ‘momentous step’ for HIV prevention
Gilead’s recently approved drug for HIV prevention, Yeztugo (lenacapavir), has the potential to transform the pre-exposure prophylaxis (PrEP) sector in…
-
Vertex wins European approval for Alyftrek, bolstering cystic fibrosis stronghold
Vertex Pharmaceuticals has won approval in Europe for its next-generation cystic fibrosis therapy Alyftrek (deutivacaftor/tezacaftor/vanzacaftor), shoring up the company’s dominance…
-
Oncternal sells assets for up to $68m and calls it quits
American oncology company Oncternal Therapeutics is to wind down operations after announcing the sale of its main drug programmes. Delaware-based…
-
AbbVie buys $2.1bn Capstan, adding new in vivo CAR-T to pipeline
AbbVie has agreed to acquire Capstan Therapeutics for up to $2.1bn, adding a “high-risk, high-reward” clinical-stage in vivo CAR-T candidate…